Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Advantage TPros prostate treatment claims draw FDA warning letter.

This article was originally published in The Tan Sheet

Executive Summary

HEALTH ADVANTAGE TPROS BPH TREATMENT CLAIMS DRAW WARNING LETTER from FDA dated Jan. 17 admonishing the company for suggesting that Dr. Mutter's TPros caplets (formerly PRos Care) are useful in treating and/or preventing benign prostatic hypertrophy and its symptoms. One claim highlighted by the agency states: "This unique combination of all-natural elements, Serenoa repens, Pygeum Africanum, zinc picolinate, vitamin B6 and nettle root extract works to relieve the nagging symptoms of an enlarged prostate...as well as contribute to improved sexual performance."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel